ftInvstr
WANBURY · Healthcare ₹201.0 +0.0% Mkt Cap ₹696 Cr

WANBURY

Healthcare Drug Manufacturers - Specialty & Generic
₹201.0
+0.0% today · 30d +2.97%
as of 2026-11-09
Price · Daily Candles
AI narrative is temporarily unavailable for WANBURY. The deterministic sections below render from live data.
₹ Latest Earnings · Q ending 2026-09-30
REVENUE
₹183 Cr
+14.28% YoY
NET PROFIT
₹9 Cr
-43.83% YoY
OPM
12.49%
-3.73pp YoY
EPS
₹2.44
PE 12.33
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-3.3% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
PEERPEROCE %
WANBURY12.3337.0
SUNPHARMA37.7921.44
DIVISLAB93.121.56
ZYDUSLIFE28.424.22
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
52
SCORE / 100
Overall
6-axis composite of the sections below.
Performance UNDERPERFORMER 20
Valuation CHEAP 75
Growth DECLINING 28
Profitability HIGH 78
Technicals WEAK 40
Risk LOW 70
Key Stats
TTM PE
12.33
P/B
4.85
52W HIGH
₹358.85
OFF HIGH
-43.99%
DIV YIELD
0.0%
MKT CAP
₹696 Cr
◉ Active Signals
MACDNeutral4.1327
RSI(14)Neutral53.67
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold WANBURY and at what entry.

Sign up freeSign in